🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  2. CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02

    Hoffmann-La Roche

    RET fusion−positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. CARBOPLATIN, PACLITAXEL, DOCETAXEL, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  4. CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride

    Sarepta Therapeutics

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial

  5. CEFTAZIDIME, PIPERACILLIN, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE, CEFTAZIDIME, CEFEPIME , CEFEPIME, MEROPENEM , TAZOBACTAM, TAZOBACTAM, MEROPENEM, AMIKACIN , AMIKACIN, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR , AVIBACTAM, CEFTAZIDIME

    Pari Pharma GmbH

    antibiotic therapy in Sepsis

    phase 3 small molecule active

    1 trial

  6. CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable, Clarithromycine EG 500 mg comprimés pelliculés, MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable

    Pari Pharma GmbH

    Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes

    phase 3 small molecule active

    1 trial

  7. CEFTRIAXONE, AMOXICILLIN, AZITHROMYCIN

    Pari Pharma GmbH

    Population of study participants Pregnant women with PPROM at 22 to 33 weeks’ gestation

    phase 3 small molecule active

    1 trial

  8. CF101

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  9. CF101 2mg

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  10. CHAMPIX 0.5 mg film-coated tablets, Placebo CHAMPIX ® 0.5mg Comprimé pelliculé

    Pari Pharma GmbH

    Smokers smoking at least 10 cigarettes/day in the past year

    phase 3 small molecule active

    1 trial

  11. CHF6001 DPI, CHF6001 DPI, Placebo to match CHF6001 DPI

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis

    phase 3 small molecule active

    1 trial

  12. CHLORAMBUCIL, FLUDARABINE PHOSPHATE, Lisaftoclax, ACALABRUTINIB, Lisaftoclax, Lisaftoclax, RITUXIMAB, CYCLOPHOSPHAMIDE MONOHYDRATE, RITUXIMAB

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  13. CHLORURE DE POTASSIUM B. BRAUN 10 % (0,10 g/ml), solution à diluer pour perfusion, GLUCOSE 2,5 % B. BRAUN, solution pour perfusion, MINIRIN 4 microgrammes/ml, solution injectable, SODIUM LACTATE, CHLORURE DE SODIUM 0,9 % AGUETTANT, solution pour perfusion, CHLORURE DE SODIUM HYPERTONIQUE 10 % LAVOISIER, solution à diluer injectable, GLUCOSE 5 % VIAFLO, solution pour perfusion, GADOTERIC ACID

    Pari Pharma GmbH

    Severe hyponatremia and a high risk of rapid SNa overcorrection

    phase 3 small molecule active

    1 trial

  14. CHLORURE DE SODIUM 0,9% RENAUDIN, solution injectable, VENLAFAXINE, KETAMINE , 11C-UCB-J

    Pari Pharma GmbH

    Major depressive disorder with current severe major depressive episode

    phase 3 small molecule active

    1 trial

  15. CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable, Tislelizumab

    The George Institute

    patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment

    phase 3 small molecule active

    1 trial

  16. CHS-1420

    Coherus Oncology

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  17. CIPROFLOXACIN, Upadacitinib, Upadacitinib, METHOTREXATE, SULFASALAZINE, Upadacitinib, Upadacitinib, DEXAMETHASONE, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  18. CISPLATIN

    Ningbo Cancer Hospital

    Ovarian epithelial cancer : intraperitoneal resectable relapse

    phase 3 small molecule active

    1 trial

  19. CISPLATIN , PACLITAXEL , GEMCITABINE , CARBOPLATIN , placebo for mRNA-4157, PEMETREXED , mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. CISPLATIN, Armisarte 25 mg/ml concentrate for solution for infusion, CARBOPLATIN, PEMETREXED, TAGRISSO 80 mg film-coated tablets, PLACEBO, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease

    phase 3 small molecule active

    1 trial

  21. CISPLATIN, BL-B01D1, GEMCITABINE, PEGFILGRASTIM, CARBOPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  22. CISPLATIN, CARBOPLATIN

    Cardiff Oncology

    Human papillomavirus (HPV)-positive oropharyngeal cancer

    phase 3 small molecule active

    1 trial

  23. CISPLATIN, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, GEMCITABINE, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, GEMCITABINE

    AstraZeneca AB

    Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  24. CISPLATIN, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, PEMETREXED, CARBOPLATIN, CISPLATIN, AMIVANTAMAB, AMIVANTAMAB, CARBOPLATIN, CARBOPLATIN, PEMETREXED, OSIMERTINIB, PEMETREXED

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources